Literature DB >> 30988556

Heterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD).

Salar Abbas1, Sanjay Kumar1, Vivi M Srivastava2,3, Marie Therese M3, Sukesh C Nair4, Aby Abraham5, Vikram Mathews5, Biju George5, Alok Srivastava1,5.   

Abstract

Bone marrow niche constituents have been implicated in the genesis of clonal hematopoietic dysfunction in myelodysplastic syndromes (MDS), though the exact role of stroma in the pathogenesis of MDS remains to be defined. We have evaluated the characteristics of mesenchymal stromal cells in a cohort of patients with MDS with multilineage dysplasia (MDS-MLD). MSCs were cultured from bone marrow aspirates of MDS-MLD patients and controls with healthy bone marrow. Phenotypic characterization, cell cycle, and apoptosis were analyzed by flow cytometry. Targeted gene expression analysis was done using a reverse-transcription polymerase chain reaction (Q-PCR). MSCs derived from MDS patients (MDS-MSCs) showed normal morphology, phenotype, karyotype and differentiation potential towards adipogenic and osteogenic lineages. However, these MDS-MSCs showed significantly altered cell cycle status and displayed a shift towards increased apoptosis compared to control MSCs (C-MSCs). The gene expression profile of niche responsive/regulatory cytokines showed a trend towards lower expression VEGF, SCF, and ANGPT with no changes in expression of CXCL12A and LIF compared to C-MSCs. The expression levels of Notch signaling components like Notch ligands (JAGGED-1 and DELTA-LIKE-1), receptors (NOTCH1, NOTCH3) and downstream gene (HES1) showed an aberrant expression pattern in MDS-MSCs compared to C-MSCs. Similarly, Q-PCR analysis of Wnt signaling inhibitory ligands (DKK-1 and DKK-2) in MDS-MSCs showed a three-fold increase in mRNA expression of DKK1 and a two-fold increase in DKK2 compared to C-MSCs. These data suggested that MDS-MSCs have an altered proliferation characteristic as well as a dysregulated cytokine secretion and signaling profile. These changes could contribute to the pathogenesis of MDS.

Entities:  

Keywords:  Hematopoietic stem; Mesenchymal stromal cells; Myelodysplastic syndrome; Progenitor cells

Year:  2019        PMID: 30988556      PMCID: PMC6439082          DOI: 10.1007/s12288-018-1062-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  26 in total

1.  Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.

Authors:  Tatsuki Sugiyama; Hiroshi Kohara; Mamiko Noda; Takashi Nagasawa
Journal:  Immunity       Date:  2006-12       Impact factor: 31.745

2.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

3.  Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.

Authors:  Masakazu Sawanobori; Shuichi Yamaguchi; Maki Hasegawa; Miori Inoue; Kenshi Suzuki; Ryuichi Kamiyama; Katsuiku Hirokawa; Masanobu Kitagawa
Journal:  Leuk Res       Date:  2003-07       Impact factor: 3.156

4.  In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome.

Authors:  Eugenia Flores-Figueroa; Guillermo Gutiérrez-Espíndola; Juan José Montesinos; Rosa María Arana-Trejo; Hector Mayani
Journal:  Leuk Res       Date:  2002-07       Impact factor: 3.156

5.  Multilineage potential of adult human mesenchymal stem cells.

Authors:  M F Pittenger; A M Mackay; S C Beck; R K Jaiswal; R Douglas; J D Mosca; M A Moorman; D W Simonetti; S Craig; D R Marshak
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

6.  Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization.

Authors:  Eugenia Flores-Figueroa; Rosa Maria Arana-Trejo; Guillermo Gutiérrez-Espíndola; Adrián Pérez-Cabrera; Hector Mayani
Journal:  Leuk Res       Date:  2005-02       Impact factor: 3.156

7.  Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes.

Authors:  Mirjam Klaus; Emily Stavroulaki; Maria-Christina Kastrinaki; Persefoni Fragioudaki; Krinio Giannikou; Maria Psyllaki; Charalampos Pontikoglou; Debbie Tsoukatou; Clio Mamalaki; Helen A Papadaki
Journal:  Stem Cells Dev       Date:  2010-07       Impact factor: 3.272

8.  "In vitro" evaluation of bone marrow angiogenesis in myelodysplastic syndromes: a morphological and functional approach.

Authors:  Diana Campioni; Marina Punturieri; Antonella Bardi; Sabrina Moretti; Elisa Tammiso; Francesco Lanza; Gianluigi Castoldi
Journal:  Leuk Res       Date:  2004-01       Impact factor: 3.156

Review 9.  The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites.

Authors:  Y Shiozawa; A M Havens; K J Pienta; R S Taichman
Journal:  Leukemia       Date:  2008-02-28       Impact factor: 11.528

10.  Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome.

Authors:  O Lopez-Villar; J L Garcia; F M Sanchez-Guijo; C Robledo; E M Villaron; P Hernández-Campo; N Lopez-Holgado; M Diez-Campelo; M V Barbado; J A Perez-Simon; J M Hernández-Rivas; J F San-Miguel; M-C del Cañizo
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

View more
  2 in total

Review 1.  Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies.

Authors:  Xiaofang Chen; Ningyu Li; Jianyu Weng; Xin Du
Journal:  Front Cell Dev Biol       Date:  2021-02-11

Review 2.  Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.

Authors:  Bruno Fattizzo; Juri A Giannotta; Wilma Barcellini
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.